ALDEI.PA Stock Analysis
AL
Uncovered
Deinove SA is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Deinove SA is a biotechnology company, which engages in the development of new-generation anti-infective antibiotics and bioactives. The company is headquartered in Grabels, Occitanie and currently employs 44 full-time employees. The company went IPO on 2010-04-21. The company specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value. The processes developed by Deinove use the natural properties of Deinococcus bacteria. The green chemistry process includes the production of organic acids, such as succinic, lactic, fumaric and butyric acids used in the petrochemical, pharmaceutical, cosmetics and food industries. In addition, the Company is engaged in the production of antibiotics and antifungal agents. Deinove SA operates with such industrial companies as Tereos, CNRS, VTT, BENP-Lillebonne and Nosopharm, among others. The firm's main shareholder is Fonds Truffle Capital. The company operates through DEINOBIOTICS and Deinobiotics SAS, among others.